Literature DB >> 7338564

Toxicologic evaluation of bumetanide, potent diuretic agent.

R M McClain, K D Dammers.   

Abstract

The studies reported represent the preclinical toxicologic evaluation of bumetanide. Toxicity testing in rats, rabbits, dogs, and baboons indicate that bumetanide is well tolerated in various species. The toxicity that was observed is, for the most part, the direct consequence of its potent diuretic activity and is similar to that produced by other "loop" diuretics. Bumetanide was fetotoxic at maternal toxic doses in the rabbit, but no evidence of teratogenic effects was observed in rabbits, rats, mice, or hamsters. The compound was devoid of mutagenic activity by the Ames test and was found to be noncarcinogenic in long-term rat studies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7338564     DOI: 10.1002/j.1552-4604.1981.tb05663.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

1.  Na(+)-K (+)-2Cl (-) cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4.

Authors:  Elton R Migliati; Mahmood Amiry-Moghaddam; Stanley C Froehner; Marvin E Adams; Ole Petter Ottersen; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2010-08       Impact factor: 3.210

Review 2.  Disruption of ion homeostasis in the neurogliovascular unit underlies the pathogenesis of ischemic cerebral edema.

Authors:  Arjun Khanna; Kristopher T Kahle; Brian P Walcott; Volodymyr Gerzanich; J Marc Simard
Journal:  Transl Stroke Res       Date:  2013-11-22       Impact factor: 6.829

3.  Inhibition of aquaporin-1 and aquaporin-4 water permeability by a derivative of the loop diuretic bumetanide acting at an internal pore-occluding binding site.

Authors:  Elton Migliati; Nathalie Meurice; Pascale DuBois; Jennifer S Fang; Suma Somasekharan; Elizabeth Beckett; Gary Flynn; Andrea J Yool
Journal:  Mol Pharmacol       Date:  2009-04-29       Impact factor: 4.436

Review 4.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.